Treatment Of Chronic Bronchiectasis Pinggan Qingfei Remission (Partial Liver YangKangsyndrome) Clinical Observation

Objective: Treatment of Bronchiectasis by Pinggan Qingfei remission (partial liver yang hyperactivity syndrome) clinical validation studies, observation of Chinese medicine in the treatment of bronchiectasis with chronic remission (partial liver yang hyperactivity syndrome) clinical efficacy for the treatment of chronic bronchiectasis remission (partial liver yang hyperactivity card) clinical study provide strong evidence. And to explore and study in remission from chronic bronchiectasis chronic carbuncle on the Treatment of Lung to lung deficiency, liver Wang, partial liver Yang Kang is the key to the pathogenesis, The establishment of clearing the lungs of the law Pinggan, so as to develop chronic bronchiectasis remission treatment of new ideas and lay a solid foundation. Chinese medicine is not fully reflect disease prevention, disease prevention that change, the more complex the concept of defense.Methods: From January 2010 to October 2010 Affiliated Hospital of Changchun University of Traditional Chinese Medicine clinics and Respiratory Medicine, chronic bronchodilator therapy area remission (partial liver yang hyperactivity syndrome) patients included 48 patients divided into treatment group and control group 24.Treatment group were self treating side Pinggan Qingfei the control group treated with antibiotics, if the penicillin sensitivity test negative to amoxicillin clavulanate potassium tablets (4:1), 0.3125g, 3/day, oral; if penicillin allergy, for ciprofloxacin hydrochloride tablets, 0.25,2/day, orally, for taking 2 weeks. Evaluation of 48 patients clinical symptoms before and after treatment to improve the situation, and compared.Results: Treatment group: 3 cases of clinical control, 17 cases markedly effective in 3 cases, 1 patient, the total effective rate was 95.8%. Control group: Clinical Control 0 cases, effective in 9 cases, effective in 14 cases, 3 cases, 87.5%. Comparing the treatment groups were significantly better than the control group, P≤0.01.Conclusion: Chronic bronchodilator therapy group for remission (partial liver yang hyperactivity card) improvement in clinical symptoms than the control group, and safety, is worthy of clinical application.